HCQ and covid pathology

Published: August 26, 2020

In recent weeks, several more prospective and retrospective studies have confirmed the effectiveness of malaria drug HCQ against covid-19, both in primary care and in hospitals, and both in the general population and in nursing homes. The studies typically found risk reductions between 30% and 50% (e.g. reduced hospitalizations, disease duration or mortality).

At this point it is rather obvious that Western health authorities falsely discarded HCQ based on the fraudulent Surgisphere “study” (using fake data) and the misdesigned WHO trials (using lethal doses in late-stage disease), while pushing much more expensive and risky drugs. As a former French health minister explained in May, where some see disease, others see dollars.

Meanwhile, German pathologists found that the risk of lung microthrombosis in severe covid is about nine times higher compared to influenza (English video). They also found that the new coronavirus can use not only the ACE2 receptor, but also the NRP1 receptor, which explains the frequent olfactory symptoms (viz. the temporary loss of the sense of taste or smell).

Given what we now know about severe covid, but also about widespread post-acute “long covid” in younger and previously healthy people, health authorities should seriously consider large-scale prophylactic and early treatment based on simple, safe and effective means.

Stages of covid disease (EVMS)


Up ↑